News
Novo claims the defendants are steering patients toward compounded semaglutide that has not been approved by regulators; in ...
Novo Nordisk CFO Karsten Munk Knudsen tells Yahoo Finance the company understands the pressure it is under to deliver better ...
The FDA says shortages of GLP-1s are over, but many patients are still getting what are essentially copied medications.
It’s the most high-profile example yet of a controversial industry practice called preferred pharmacy networks, or PPNs ...
Novo Nordisk is to cut costs as the Wegovy-maker battles competition from rival Eli Lilly and copycat versions of its obesity ...
Weight-loss patients voice concerns as CVS Caremark drops Zepbound coverage for Wegovy, though exceptions may exist for those ...
Novo Nordisk faces a critical phase with its obesity drug Wegovy as it confronts competition from Eli Lilly and potential job ...
Weight loss medications like Wegovy can be life-changing for people living with obesity or excess weight with related health ...
1dOpinion
The market is driving prices on GLP-1 drugs down, and an added benefit is lower spending on food.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback